The stock rallied by 10 per cent in the last two trading sessions. The company in the September 2014 quarter reported 5.2 per cent rise in Q2FY15 net profit at Rs 91.50 crore when compared with Rs 87 crore in Q2FY14. Total income rose by 18.4 per cent to Rs 1,161 crore from Rs 980.53 crore.
Zydus Wellness at 52-week high
The stock has soared 16 per cent in the last two trading days. The company recently reported 8.4 per cent growth in Q2 net profit at Rs 27.81 crore for the quarter ended September 2014 as against Rs 25.65 crore in the corresponding quarter a year ago. Total income was up 5.5 per cent at Rs 103.03 crore from Rs 97.69 crore.
Eicher Motors stock surges 4%
Shares of Eicher Motors was up 4% at Rs14617 on reports that VE Commercial Vehicles, a 50:50 joint venture is aiming to capture the number one position in the light-to-medium duty (LMD) trucks segment in terms of market share
M&M to recall 2,300 vehicles
M&M to recall 2,300 vehicles; sentimentally negative, no significant financial impact Mahindra & Mahindra will be recalling 2,300 units of different variants of models Scorpio, Xylo and XUV 500 to rectify a defective vacuum pump in engines.
Tata Global plans to launch new green tea products
Tata Global Beverages looking to cash in on the growing awareness on health and wellness to reinforce its dominance in the green tea segment in the country by launching new products and tapping small towns. Green tea accounts for just Rs300 crore or 1.5% of total tea sales of about Rs20,000 crore in India, but the segment is growing at 50% a year.
Aurobindo Pharma eyes revenue from peptide business
Aurobindo Pharma sees new revenue stream from peptide business in FY2017-18; positive read through.Aurobindo Pharma is set to up the focus on its peptide business and will be filing its first set of drug master files (DMFs) by the end of this fiscal. Another set of DMF (for two more products) would be filed in 12 months.
Ranbaxy sues USFDA for revoking tentative approvals
Ranbaxy Lab has sued the US Food and Drug Administration ( USFDA) for revoking approvals granted to the firm to launch copies of two drugs including AstraZeneca Plc's heartburn pill Nexium. It may be noted that the USFDA revoked a tentative approval for Ranbaxy Lab to make a cheap copy of AstraZeneca Plc's heartburn drug Nexium (market size US$2.2bn) and Roche Holding AG's antiviral Valcyte (market size US$195mn) during early this month, saying that the approvals was given erroneously.
0 comments:
Post a Comment